GlassScriptPhysician profile
Sathya Subbiah
NPI 1033128764
$2,525.13
in general payments reported to CMS, 2019-2025
25 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $112 · 2021: $936 · 2022: $255 · 2023: $181 · 2024: $514 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.62 | 2019-2024 | Jardiance |
| Dexcom, INC. | $348.90 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $201.77 | 2021-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $180.36 | 2023-2024 | |
| Radius Health, INC. | $142.05 | 2022-2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $117.38 | 2019 | |
| Abbott Laboratories | $115.57 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $89.62 | 2021-2022 | |
| Abbvie INC. | $84.87 | 2021-2024 | Synthroid |
| Xeris Pharmaceuticals, INC. | $70.52 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $63.54 | 2021-2022 | |
| Beta Bionics, INC. | $62.07 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $61.87 | 2021-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $49.62 | 2021 | |
| Corcept Therapeutics | $44.89 | 2022-2024 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $42.39 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $29.98 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $28.21 | 2021-2024 | Omnipod |
| Medtronic, INC. | $27.53 | 2021 | |
| Esperion Therapeutics, INC. | $23.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2021 | |
| Merck Sharp & Dohme LLC | $12.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.38 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathya Subbiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.